155 related articles for article (PubMed ID: 37396000)
1. Outcome of inflammatory bowel disease patients with prior malignancy.
Shani U; Klang E; Lassman S; Ungar B; Ben-Horin S; Kopylov U
Ann Gastroenterol; 2023; 36(4):405-411. PubMed ID: 37396000
[TBL] [Abstract][Full Text] [Related]
2. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
3. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.
Townsend CM; Khanna R; Wilson AS
Dig Dis Sci; 2021 Dec; 66(12):4436-4440. PubMed ID: 33428042
[TBL] [Abstract][Full Text] [Related]
4. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
[TBL] [Abstract][Full Text] [Related]
5. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
7. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
Poullenot F; Amiot A; Nachury M; Viennot S; Altwegg R; Bouhnik Y; Abitbol V; Nancey S; Vuitton L; Peyrin-Biroulet L; Biron A; Fumery M; Picon L; Vidon M; Reenaers C; Serrero M; Savoye G; Beaugerie L; Rivière P; Laharie D
J Crohns Colitis; 2022 Nov; 16(10):1523-1530. PubMed ID: 35512337
[TBL] [Abstract][Full Text] [Related]
8. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
Muller M; D'Amico F; Bonovas S; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 May; 15(5):840-859. PubMed ID: 32915970
[TBL] [Abstract][Full Text] [Related]
9. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.
Poullenot F; Seksik P; Beaugerie L; Amiot A; Nachury M; Abitbol V; Stefanescu C; Reenaers C; Fumery M; Pelletier AL; Nancey S; Peyrin-Biroulet L; Bourreille A; Hébuterne X; Brixi H; Savoye G; Lourenço N; Altwegg R; Buisson A; Cazelles-Boudier C; Racine A; Vergniol J; Laharie D;
Inflamm Bowel Dis; 2016 Jun; 22(6):1362-9. PubMed ID: 26919458
[TBL] [Abstract][Full Text] [Related]
10. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
[TBL] [Abstract][Full Text] [Related]
12. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
13. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
14. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
Holmer AK; Luo J; Russ KB; Park S; Yang JY; Ertem F; Dueker J; Nguyen V; Hong S; Zenger C; Axelrad JE; Sofia A; Petrov JC; Al-Bawardy B; Fudman DI; Llano E; Dailey J; Jangi S; Khakoo N; Damas OM; Barnes EL; Scott FI; Ungaro RC; Singh S;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1598-1606.e5. PubMed ID: 36642291
[TBL] [Abstract][Full Text] [Related]
15. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
[TBL] [Abstract][Full Text] [Related]
16. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
Cosnes J
Dig Dis; 2017; 35(1-2):50-55. PubMed ID: 28147366
[TBL] [Abstract][Full Text] [Related]
17. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
[TBL] [Abstract][Full Text] [Related]
18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
19. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
20. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
Dheyriat L; Ward D; Beaugerie L; Jess T; Kirchgesner J
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):164-172.e11. PubMed ID: 35842123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
